Roche Holding (SWX:ROG) experienced a 14% increase in share price over the last quarter, driven in part by several key ...

Discover March 2025’s top biotech deals, featuring major collaborations in small molecules, bispecific antibodies and protein ...

Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

Coming to you well over a month late, we still want to acknowledge the many comings and goings we saw in the biotech industry in April. Stay tuned for a combined May-June edition to get us back on ...

Wake up with Oxfordshire's latest news, great music and conversation with Sophie.